Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid–gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration - 03/09/11
Abstract |
PURPOSE: To evaluate a new procedure for displacement of large, thick submacular hemorrhage in patients with age-related macular degeneration.
METHODS: Retrospective review of 11 eyes of 11 patients with age-related macular degeneration and thick submacular hemorrhage (defined as causing retinal elevation detectable on stereo fundus photographs) treated with vitrectomy, subretinal injection of tissue plasminogen activator (25 or 50 μg), and fluid–gas exchange with postoperative prone positioning. Outcome measures included displacement of hemorrhage from the fovea, best postoperative visual acuity, and final postoperative visual acuity.
RESULTS: In the 11 affected eyes of 11 patients (seven men and four women; mean age, 76 years), preoperative visual acuity ranged from 20/200 to hand motions. With surgery, subretinal hemorrhage was displaced from the fovea in all 11 cases. Mean postoperative follow-up was 6.5 months (range, 1 to 15 months). Best postoperative visual acuity varied from 20/30 to 5/200, with improvement in nine (82%) cases and no change in two cases. Eight eyes (73%) measured 20/200 or better, with four of these eyes (36%) 20/80 or better. Final postoperative visual acuity ranged from 20/70 to light perception, with improvement in eight (73%) cases, no change in one case, and worsening in two cases. A statistically significant difference was found between preoperative and best postoperative visual acuity (P = .004) but not between preoperative and final visual acuity (P = .16). Hemorrhage recurred in three (27%) eyes, causing severe visual loss in one eye.
CONCLUSIONS: This technique displaces submacular hemorrhage from the fovea and can improve vision in patients with age-related macular degeneration. However, recurrence of hemorrhage occurred in 27% of eyes and caused severe visual loss in one eye. A randomized, prospective clinical trial is necessary to determine the efficacy of this technique in comparison with other proposed treatments.
Le texte complet de cet article est disponible en PDF.Plan
| ☆ | This work is supported by Core Grant P30-EYO5722 from the National Institutes of Health, Bethesda, Maryland. Dr Jaffe is a Lew R. Wasserman Merit Award recipient from Research to Prevent Blindness, New York, New York. Dr Steuer was supported by an AOS-Knapp fellowship. |
Vol 131 - N° 2
P. 208-215 - février 2001 Retour au numéro
Article précédent
- Treatment of retinal detachment resulting from myopic macular hole with internal limiting membrane removal
- Kazuaki Kadonosono, Futoshi Yazama, Norihiko Itoh, Eiichi Uchio, Satoshi Nakamura, Junsuke Akura, Hajime Sawada, Shigeaki Ohno
- Retinal nerve fiber layer evaluation in human immunodeficiency virus–positive patients
- Daniel J Plummer, Dirk-Uwe G Bartsch, Stanley P Azen, Sara Max, Alfredo A Sadun, William R Freeman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?